Repeated exercise, or wasting, can change the way key genes work.

Alterity Therapeutics is a late clinical-stage biotech company focused on developing treatments for serious neurodegenerative ...

Multiple sclerosis (MS) is a chronic neurological disease characterized by nerve damage and consequent impairments in vision, ...

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

Longtime Texas high school football coach Mike Robinson has died, DeSoto coach Claude Mathis confirmed to The Dallas Morning ...

In a clinical trial spanning two years, lipoic acid was shown to slow brain atrophy in people with progressive multiple sclerosis. However, the antioxidant failed to ease symptoms such as fatigue.

ST. LOUIS – Amid his absence on FOX 2 News in the morning, Tim Ezell is sharing the latest on his health journey after a trip to the Mayo Clinic. Margie Ellisor took a visit to Tim’s home this week to ...

A new study found paramagnetic rim lesions, indicating chronic inflammation, in nearly 75% of children with MS. More lesions, or PRLs, correlate with faster brain atrophy, suggesting aggressive ...

Inflammasome Therapeutics Completes Enrollment of Multicenter Phase II Dose- Ranging Study for First-in-Class Dual Inflammasome Inhibitor, K8, to Treat Geographic Atrophy Inflammasome Therapeutics, a ...

Robert Spignesi, CEO, opened by highlighting third quarter revenue of $7.8 million, which was above the midpoint of guidance and marked the twelfth consecutive quarter meeting or beating revenue ...

HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...